The Value of and Challenges for Cholera Vaccines in Africa

被引:11
|
作者
von Seidlein, Lorenz [1 ]
Jiddawi, Mohammad [2 ]
Grais, Rebecca F. [3 ]
Luquero, Francisco [3 ]
Lucas, Marcelino [4 ]
Deen, Jacqueline [1 ]
机构
[1] Menzies Sch Hlth Res, Casuarina, NT 0810, Australia
[2] Minist Hlth, Zanzibar, Tanzania
[3] Epicentre, Paris, France
[4] Minist Hlth, Maputo, Mozambique
来源
关键词
cholera; vaccine; OCV; Africa; review; VIBRIO-CHOLERAE; FIELD TRIAL; VACCINATION; LIVE; BANGLADESH; CLIMATE; COST; O1; CONSTRUCTION; CANDIDATE;
D O I
10.1093/infdis/jit194
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The 21st century saw a shift in the cholera burden from Asia to Africa. The risk factors for cholera outbreaks in Africa are incompletely understood, and the traditional emphasis on providing safe drinking water and improving sanitation and hygiene has proven remarkably insufficient to contain outbreaks. Current killed whole-cell oral cholera vaccines (OCVs) are safe and guarantee a high level of protection for several years. OCVs have been licensed for > 20 years, but their potential for preventing and control cholera outbreaks in Africa has not been realized. Although each item in the long list of technical reasons why cholera vaccination campaigns have been deferred is plausible, we believe that the biggest barrier is that populations affected by cholera outbreaks are underprivileged and lack a strong political voice. The evaluation and use of OCVs as a tool for cholera control will require a new, more compassionate, less risk-averse generation of decision makers.
引用
收藏
页码:S8 / S14
页数:7
相关论文
共 50 条
  • [1] The value of cholera vaccines reassessed
    Glass, RI
    Steele, AD
    LANCET, 2005, 366 (9479): : 7 - 9
  • [2] The opportunities & challenges in delivering oral cholera vaccines
    Deen, Jacqueline
    Sack, David A.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2016, 144 : 149 - 150
  • [3] Cholera vaccines
    Loebermann, Micha
    Borso, Denise
    Hilgendorf, Inken
    Fritzsche, Carlos
    Zettl, Uwe K.
    Reisinger, Emil C.
    AUTOIMMUNITY REVIEWS, 2011, 11 (02) : 158 - 158
  • [4] Cholera vaccines
    Ryan, ET
    Calderwood, SB
    JOURNAL OF TRAVEL MEDICINE, 2001, 8 (02) : 82 - 91
  • [5] Cholera vaccines
    Kabir, Shahjahan
    LANCET INFECTIOUS DISEASES, 2007, 7 (03): : 176 - 178
  • [6] Cholera vaccines
    Ryan, ET
    Calderwood, SB
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) : 561 - 565
  • [7] Cholera vaccines
    Fournier, JM
    Fauve, RM
    BULLETIN DE L INSTITUT PASTEUR, 1995, 93 (04): : 227 - 227
  • [8] Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges
    Deen, Jacqueline
    Holmgren, Jan
    Clemens, John D.
    LANCET INFECTIOUS DISEASES, 2022, 22 (10): : E292 - E298
  • [9] PERSPECTIVES OF CHOLERA VACCINES
    VALDESPINOGOMEZ, JL
    ISIBASIARAUJO, A
    HINOJOSAAHUMADA, MA
    GIONOCEREZO, S
    SALUD PUBLICA DE MEXICO, 1993, 35 (01): : 3 - 19
  • [10] Cholera vaccines - Reply
    Ford, Lisa
    Lalloo, David G.
    Hill, David R.
    LANCET INFECTIOUS DISEASES, 2007, 7 (03): : 178 - 178